<DOC>
	<DOCNO>NCT00858806</DOCNO>
	<brief_summary>Standard therapy Imatinib ( IM ) significantly prolong survival Ph+CML patient obtain complete cytogenetic response ( CCgR ) . Elderly patient ( i.e. , least 65 year ) similar cytogenetic response survival , usually show low compliance . The aim study evaluate percentage elderly patient maintain CCgR intermittent imatinib therapy respect standard daily administration .</brief_summary>
	<brief_title>Intermittent Imatinib Treatment Chronic Myeloid Leukemia Philadelphia Chromosome ( Ph+CML ) Patients Who Achieved Complete Cytogenetic Response ( CCgR ) Standard Imatinib Therapy</brief_title>
	<detailed_description>Objective : The aim study investigate complete cytogenetic response ( CCgR ) achieve standard ( daily administration ) Imatinib ( IM ) therapy maintain dose IM give intermittently ( INTERIM ) . For purpose study , term `` standard IM therapy '' mean daily administration IM dose 300 800mg , whereas , `` intermittent IM treatment '' ( INTERIM ) , define daily dose IM give one month on/one month . The primary objective study evaluate proportion patient remain CCgR INTERIM give one year . Study design : This study open-label , multicenter , Phase II study INTERIM maintenance CCgR . Study Population : Elderly patient ( least 65 year ) Ph+ CML stable CCgR least 2 year standard ( daily administration ) IM therapy Treatment Plan STUDY DRUG : Imatinib register Glivec Novartis Pharma Italy treatment patient Ph+ CML phase ( CP AP/BP ) . DOSE AND SCHEDULE : Imatinib ( Glivec ) give daily dose give time enrollment follow intermittent schedule : - 1 week / 1 week 1st month ( week 1-4 ) - 2 week / 2 week 2nd 3rd month ( week 5-12 ) - 1 month / 1 month 4th month thereafter ( week 13 ) TREATMENT DURATION : The study duration 12 month . After 12 month intermittent dose IM ( INTERIM ) patient continuous CCgR advise continue study treatment dose ( INTERIM ) go back pre-study daily dose . Follow require indefinitely patient . Efficacy The primary efficacy variable intermittent dose IM ( INTERIM ) measure proportion patient maintain stable CCgR whole study period ( 12 month ) . For purpose study monitor cytogenetic response ( CgR ) status evaluate Fluorescence-in-situ-Hybridization ( FISH ) interphase peripheral blood cell ( molecular cytogenetic analysis ) OFF TREATMENT EVENTS Patients go study case failure : - Loss CCgR - Loss CHR - Progression AP/BP case : - Patient 's refusal - Documentation serious adverse event ( SAE ) - Protocol violation OFF-TREATMENT THERAPEUTIC RECOMMENDATIONS - In case Loss CCgR - intermittent dose IM ( INTERIM ) STOPPED - evaluation additional cytogenetic abnormality ( ACA ) conventional ( morphologic ) cytogenetics perform - mutational analysis BCR-ABL transcript check - pre-study IM standard therapy ( daily dose administration ) RESUMED - In case Loss CHR Disease Progression AP/BP - intermittent dose IM ( INTERIM ) STOPPED - recommend move investigational available treatment , base cytogenetic molecular data - In case SAE : recommend discontinue IM forever - In case Refusal Protocol Violation : recommend go back pre-study IM dose Concomitant Treatments All patient enrol study already treat IM minimum 2 year . Therefore , expect problem concern concomitant treatment already consider investigator patient familiar . However , wise remind IM competitive inhibitor CYP2D6 CYP3A4/5 . Interactions possible IM administer drug whose metabolism dependent a1ter level P450 cytochrome isoenzymes . When drug classify 'substrates ' co-administered IM , potential high concentration 'substrate ' . When IM co-administered compound classified 'inhibitors ' , increase plasma concentration Imatinib potential outcome . Particular attention draw potential interaction IM acetaminophen , anticoagulant ( especially warfarin ) anticonvulsant . Visit Schedule , Assessments Follow-up - Clinical evaluation physical examination , include height , weight , vital sign relevant finding assess time enrollment ( baseline ) every 3 month study ( 12 month ) . - Cardiac function assessment perform echocardiography baseline , end study . - Blood count include Hb , Plt count , WBC differential perform baseline monitor every 3 month study . - Serum chemistry , include BUN , creatinine , AST , ALT , ALP , bilirubin , Ca , P , K Mg , total protein concentration electrophoretic profile , IgG , IgA , IgM concentration perform baseline every 3 month study . - The cytogenetic response ( CgR ) status evaluate baseline every 3 month study - At baseline ( BL ) cytogenetic response ( CgR ) status must evaluate conventional ( morphologic ) AND molecular cytogenetics ( FISH ) analysis . - The monitoring cytogenetic response ( CgR ) status ( month 3 , 6 , 9 12 ) evaluate Fluorescence-in-situ-Hybridization ( FISH ) interphase peripheral blood cell ( see section 11.1 page 19 ) . FISH potential advantage ) evaluate many cell use peripheral blood instead marrow , ii ) reduce miss information conventional morphologic evaluation marrow cell metaphase , iii ) improve compliance patient cytogenetic monitoring . - If FISH document variation baseline value 1 % , check CgR second FISH analysis 1 month - If second FISH analysis confirm variation baseline value 1 % , conventional cytogenetics evaluation marrow cell metaphase perform confirm Cytogenetic Response Loss ( CgR loss ) check additional cytogenetic abnormality ( ACA ) - Quantitative molecular assessment BCR-ABL transcript RQ-PCR peripheral blood sample due baseline every 3 month study . - Mutational analysis perform case loss CCgR marrow cell . - Follow require indefinitely patient standard hematologic , cytogenetic molecular criterion . Sample Size This study design accord optimal Simon 's two stage procedure , base data annual rate treatment failure report 454 patient receive IM multicenter , open-label , phase III randomize international study IRIS . The optimal two-stage design test null hypothesis P &lt; = 0.850 versus alternative P &gt; = 0.950 expect sample size 33.7 probability early termination 0.602 . If INTERIM regimen effective ( sense maintain complete cytogenetic response le 0.85 ) , 0.049 probability concluding ( target value 0.050 ) . If INTERIM regimen effective ( sense maintain complete cytogenetic response 0.85 ) , 0.200 probability concluding ( target value 0.200 ) . A total 78 patient enrol , 13 first stage 65 second stage . The Trial Advisory Committee ( TAC ) monitor accrual cytogenetic response status every 3 month stop study loss CCgR 15.4 % 9.2 % first second stage , respectively . Trial Time Trial time 12 month . Thereafter , patient follow standard hematologic , cytogenetic molecular criterion , indefinitely .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Patients confirm diagnosis Ph+ CML CP 2 . Age â‰¥ 65 year old 3 . Stable CCgR least 2 year treatment standard ( daily administration ) IM therapy document 2 consecutive cytogenetic analysis last 12 month 4 . Karnofsky performance status &gt; 50 % 5 . Written inform consent prior study procedure perform . 1 . Patients Ph+ CML accelerated/blastic phase ( AP/BP ) , late CP , previously treat ( i.e . IFN alpha+/ low dose AraC , Hydroxyurea , allogeneic stem cell transplantation , etc etc . ) 2 . Age &lt; 65 year old 3 . No stable CCgR least 2 year treatment standard ( daily administration ) IM therapy document 2 consecutive cytogenetic analysis last 12 month 4 . Karnofsky performance status &lt; 50 % 5 . No write informed consent prior study procedure perform .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>